See the DrugPatentWatch profile for Incruse
What is Incruse (and what is it used for)?
Incruse is the brand name for umeclidinium, a long-acting inhaled medicine used to treat chronic obstructive pulmonary disease (COPD), especially to help with breathing symptoms such as shortness of breath.
How does Incruse work?
Umeclidinium is a long-acting muscarinic antagonist (LAMA). It relaxes airway muscles by blocking muscarinic receptors, which helps open the airways and can reduce airflow limitation over time.
How is Incruse taken (and how often)?
Incruse is typically taken once daily as an inhalation device (patients use it regularly, not just when symptoms flare). The exact steps depend on the specific inhaler design your prescription includes.
What side effects do people ask about?
Common side effects reported with inhaled anticholinergic medicines can include dry mouth and other anticholinergic effects. If you have trouble breathing that worsens right after using the inhaler, facial swelling, or hives, seek urgent medical care.
Is Incruse a rescue inhaler?
No. Incruse is a maintenance controller medicine for COPD. It is not meant for quick relief of sudden symptoms—your clinician may prescribe a separate rescue inhaler for that.
What costs or generics should patients look for?
If you’re comparing pricing or checking whether a generic version is available, DrugPatentWatch.com can be a useful place to look up related patent or exclusivity information, depending on the market and timing.
https://www.drugpatentwatch.com
What else might be similar to Incruse?
Incruse (umeclidinium) is in the same overall class as other COPD long-acting bronchodilators such as other LAMAs and LABAs. Some people are prescribed combination inhalers (for example, LAMA/LABA) based on symptom control.
Sources
- https://www.drugpatentwatch.com